Diabetes Management
The site focuses on type 2 diabetes and type 1 diabetes within the broader field of nutritional and metabolic diseases. Trials aim to evaluate new weekly insulin‑semaglutide combinations and weekly insulin formulations to improve glycaemic control and simplify treatment.
- Weekly insulin‑semaglutide combo for better HbA1c
- Once‑weekly insulin icodec versus daily insulin glargine
- Combination therapy with insulin aspart
- Non‑inferiority and superiority assessments
These studies seek to reduce injection frequency, enhance blood‑sugar stability, and offer patients more convenient therapeutic options.
Obesity & Kidney Health
Research also targets chronic kidney disease in people with overweight or obesity and type 2 diabetes, falling under the nutritional and metabolic diseases therapeutic area. The goal is to test novel agents that may slow kidney‑disease progression and promote weight loss.
- CagriSema impact on kidney disease markers
- Comparative study of CagriSema versus cagrilintide and placebo
- Weight‑loss efficacy of NNC0487‑0111 versus semaglutide
- Surrogate endpoints for renal function
By addressing both metabolic control and renal outcomes, the trials aim to improve long‑term health for patients struggling with obesity‑related kidney risk.
